DK2359853T3 - Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese - Google Patents

Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese

Info

Publication number
DK2359853T3
DK2359853T3 DK10012457.7T DK10012457T DK2359853T3 DK 2359853 T3 DK2359853 T3 DK 2359853T3 DK 10012457 T DK10012457 T DK 10012457T DK 2359853 T3 DK2359853 T3 DK 2359853T3
Authority
DK
Denmark
Prior art keywords
modulating
antiogenesis
pharmaceutical compositions
methods useful
mammalian tissue
Prior art date
Application number
DK10012457.7T
Other languages
English (en)
Inventor
Gera Neufeld
Gal Akiri
Zahava Vadasz
Stela Gengrovitch
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Application granted granted Critical
Publication of DK2359853T3 publication Critical patent/DK2359853T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10012457.7T 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese DK2359853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08
EP08020754A EP2078531B1 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis

Publications (1)

Publication Number Publication Date
DK2359853T3 true DK2359853T3 (da) 2013-12-09

Family

ID=22837793

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10012457.7T DK2359853T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese
DK01958338.4T DK1315519T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose
DK10012458.5T DK2359854T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK08020754.1T DK2078531T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til modulering af angiogenese

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK01958338.4T DK1315519T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose
DK10012458.5T DK2359854T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK08020754.1T DK2078531T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til modulering af angiogenese

Country Status (9)

Country Link
EP (4) EP2359854B1 (da)
AT (1) ATE493147T1 (da)
AU (1) AU2001280056A1 (da)
CY (3) CY1111869T1 (da)
DE (1) DE60143754D1 (da)
DK (4) DK2359853T3 (da)
ES (4) ES2440932T3 (da)
PT (4) PT2359854E (da)
WO (1) WO2002011667A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2003225563A1 (en) * 2002-02-12 2003-09-04 Curagen Corporation Compositions and methods for treatment of osteoarthritis
FR2855968B1 (fr) 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
JP2007526247A (ja) 2004-01-23 2007-09-13 マサチューセッツ・アイ・アンド・イア・インファーマリー リジルオキシダーゼ様１（ｌｏｘｌ１）および弾性繊維形成
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
DE102007051006A1 (de) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stabile, synergistische Mischungen
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
AU2001261194A1 (en) * 2000-05-03 2001-11-12 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
DK2359854T3 (da) 2013-11-04
ES2358581T3 (es) 2011-05-12
EP2359853B1 (en) 2013-11-06
ES2387329T3 (es) 2012-09-20
PT2359853E (pt) 2013-12-26
HK1131912A1 (en) 2010-02-12
EP1315519B1 (en) 2010-12-29
WO2002011667A2 (en) 2002-02-14
EP2078531A3 (en) 2010-01-20
EP2078531B1 (en) 2012-05-30
PT1315519E (pt) 2011-03-17
ES2440932T3 (es) 2014-01-31
WO2002011667A3 (en) 2003-03-27
EP2078531A2 (en) 2009-07-15
DE60143754D1 (de) 2011-02-10
EP1315519A2 (en) 2003-06-04
DK1315519T3 (da) 2011-04-11
EP2359853A1 (en) 2011-08-24
ATE493147T1 (de) 2011-01-15
CY1111869T1 (el) 2015-11-04
HK1161115A1 (en) 2012-08-24
CY1113142T1 (el) 2016-04-13
HK1161113A1 (en) 2012-08-24
ES2437093T3 (es) 2014-01-08
PT2078531E (pt) 2012-08-06
DK2078531T3 (da) 2012-09-10
EP2359854A1 (en) 2011-08-24
EP2359854B1 (en) 2013-10-09
CY1114734T1 (el) 2016-12-14
EP1315519A4 (en) 2005-09-14
PT2359854E (pt) 2013-11-22
AU2001280056A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
CY1114734T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμες για ρυθμιση αγγειογενεσης
CY1115583T1 (el) Σκευασμα που περιλαμβανει μεταλλαγμα/τα της λυσοσωμικης αλφα-γαλακτοσιδασης α για τη θεραπευτικη αντιμετωπιση της νοσου fabry
EP1024827A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF ORAL VACCINES AND THERAPEUTICS
DE69023574D1 (de) Amphotere Zusammensetzungen und Polymerformen von alpha-Hydroxy-Säuren, und ihre therapeutische Anwendung.
BR9106330A (pt) Tiofeno sulfonamidas uteis como inibidores da anidrase carbonica
ATE322270T1 (de) Arzneimittel auf basis von gestagenen zur dermalen anwendung enthaltend ascorbinsäure sowie deren salze
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
NO172344C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte flavonoidforbindelser og salter
PT998287E (pt) Utilizacao de levobupivacaina
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
ATE231388T1 (de) Lang wirksames mittel zur rektalen verabreichung
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
DE69108748D1 (de) Antithrombin-Lösung und ihre Verwendung.
DK393188A (da) Farmaceutisk praeparat til intranasal administrering
DK598288A (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
DK0453603T3 (da) Piroxicamholdige farmaceutiske præparater til topisk anvendelse
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DK0450123T3 (da) Farmaceutisk præparat til topisk administration indeholdende dichlofenac-natrium
ATE189892T1 (de) Polymerisierbare aromatische carbonsäuren und carbonsäureanhydride mit cyclischen carbonatgruppen sowie zubereitungen, enthaltend diese verbindungen
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
CY1106882T1 (el) Τροποποιηση βητακυτταρουλινης
AR020815A1 (es) Procedimiento para el tratamiento de la esquizofrenia, como tambien medios para ser utilizados en dicho procedimiento
ATE309807T1 (de) Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält